DAEWOONG PHARMACEUTICAL
Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.
DAEWOONG PHARMACEUTICAL
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
1945-01-01
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Medico Intercontinental Limited
Medico Intercontinental Limited is a health care based company that aims at developing human health through pursuits in science & therapies.
Mochida Pharmaceutical
Mochida Pharmaceutical is a healthcare company provides pharmaceuticals, healthcare products, and medical equipment businesses.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-04-11 | Turn.bio | Daewoong Pharmaceutical investment in Venture Round - Turn.bio | N/A |
| 2021-08-19 | Alloplex Biotherapeutics | Daewoong Pharmaceutical investment in Corporate Round - Alloplex Biotherapeutics | 1000 K USD |
More informations about "Daewoong Pharmaceutical"
Daewoong Pharmaceutical - Wikipedia
Daewoong Pharmaceutical was established as Kawai Pharmaceutical Company in 1942. Daewoong was officially incorporated in 1945 as Daehan Vitamin Chemical and changed its name to Daehan Vitamin Industrial in 1961. In 1966, Yoon Young-hwan purchased Daehan Vitamin, which was in financial difficulties, and changed its name to the current form, Daewoong Pharmaceutical, in 1978. See details»
Daewoong Pharmaceutical (INDIA) Pvt. Ltd.
Subsequently, in November 2012, Daewoong Pharmaceutical (India) Pvt. Ltd. was established in Hyderabad. This entity was created to position itself as a Formulation and Analytical Services Contract Research Organization, catering …See details»
대웅제약
고객상담 대표번호 080-550-8308~9 주소 서울시 강남구 봉은사로 114길 12(삼성동) tel 02)550-8800 대표이사 이창재, 박성수See details»
DAEWOONGRX
Introducing Daewoong Therapeutics's corporate growth roadmap. 2025. Frontier Expansion. Feb. P1CT IND submitted for DWRX5003 (GLP-1RA, KR) Apr. NDA approval (KR) for DWRX1010. Present. Joint research collaboration under …See details»
Organization | Daewoong Pharmaceutical Co. LTD. - Purdue …
Organization Overview. First Clinical Trial. 2003 NCT02693522. First Marketed Drug. 2015 meropenem . First NDA Approval ... Daewoong Bio Inc. | Daewoong Pharmaceutical Co. LTD. …See details»
Daewoong Pharmaceutical reveals 10 years of 'Open …
Oct 16, 2024 In 2023, Daewoong Pharmaceutical established Daewoong Investment, a dedicated investment firm, to foster an environment focused on investing in promising biotech companies. Additionally, the company has …See details»
Daewoong Pharmaceutical Co., Ltd.
Briefly introducing our company, Daewoong Pharmaceutical, Co. Ltd, specialized in pharmaceutical manufacturing, R&D, CMO, and Distribution activity to supply pharmaceutical, …See details»
Daewoong Pharmaceutical - Crunchbase Investor …
Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020. Lists Featuring This Company. ... 9,094 Number of Organizations • …See details»
Daewoong Pharmaceutical - JMP
Daewoong Pharmaceutical, one of Korea’s largest pharmaceutical companies, uses big data to develop new biologic drugs in a competitive global market. Style. section-top-padding-small. Challenge. High medical costs have increased …See details»
Daewoong Pharmaceutical - The Org
Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic …See details»
Daewoong Pharmaceutical - PharmaBoardroom
Jul 12, 2018 Established in 1945, Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare …See details»
Daewoong Group - DAEWOONG PHARMACEUTICAL (INDIA) PVT.
Daewoong Pharmaceutical’s Nabota, launched in Malaysia… DWI is a total solution provider as an Indian CRO for formulation & analytical research, clinical service support, regulatory affairs …See details»
Daewoong jumps into cell therapy market as CDMO player
Jan 19, 2021 Daewoong Pharmaceutical has drawn the industry’s attention since the company announced that it would start a contract development manufacturing organization (CDMO) …See details»
Daewoong leads national project to advance organoid …
Jan 13, 2025 Daewoong Pharmaceutical said on Monday that it has been selected by the Ministry of Trade, Industry, and Energy for a project aimed at developing mass production …See details»
Daewoong Pharma’s Open Collaboration - 대웅제약
“Daewoong Pharma can provide libraries as well as support for collaborative research.” “Daewoong Pharma values every single idea. “Daewoong Pharma will offer you a cooperative …See details»
Daewoong initiates mass production of organoids for regenerative ...
Jan 13, 2025 Daewoong, a domestic pharmaceutical company, will embark on the mass production development of organoids, known as mini organs. ... Daewoong serves as the lead …See details»
Home - DAEWOONG PHARMACEUTICAL (INDIA) PVT. LTD.
In 2012 Daewoong Pharmaceutical (INDIA) Pvt. Ltd. (DWI) was incorporated as an Indian company providing contract research and development services in formulation and analytical …See details»
Daewoong Pharma’s Open Collaboration - 대웅제약
Daewoong pharma has production facilities in the level of cGMP/EU-GMP level at home and abroad, based on skilled experience and know-how accumulated over 70 years from drug …See details»
Daewoong Pharm marks record-breaking performance driven by …
Feb 10, 2025 Daewoong Pharmaceutical recorded its highest-ever revenue, operating profit, and net profit last year, driven by the remarkable growth of its new drugs, including Fexuclu and …See details»
Daewoong Announces Promising Results in Pulmonary Fibrosis Trial
13 hours ago Daewoong Pharmaceutical announced on June 4 that it presented an interim analysis poster on the global Phase 2 clinical trial design and patient enrollment status for …See details»